Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ECTRIMS 2021

- PMLiVE

Genentech announces positive clinical results for BTK inhibitor MS treatment

Multiple sclerosis affects more than 2.9 million people globally

- PMLiVE

BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation

The report shows how prehabilitation can improve patient experience while alleviating capacity pressures

- PMLiVE

BMS acquires Orbital Therapeutics in $1.5bn deal

The deal includes several next-gen cell therapy candidates for autoimmune diseases

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

The immune-mediated disease affects more than 2.9 million people worldwide

- PMLiVE

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links